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Abstract (currently 349 words) 26
Poor response to platinum/taxane-based chemotherapy has remained a major hurdle in the 27 management of high grade serous carcinoma of the ovary (HGSC). Recurrent HGSC is often 28 treated with liposomal doxorubicin as a second line chemotherapy. Unfortunately, HGSC patients 29 have not benefited from immunotherapies targeting the PD-1/PD-L1 immune checkpoint axis. In 30 a pre-clinical study evaluating the efficacy of a "Stimulator of Interferon Genes" (STING) 31 agonist, we demonstrated the synergistic potential of STING pathway activation in enhancing 32 response to carboplatin chemotherapy and sensitization to PD-1 immune checkpoint blockade 33 (ICB). Since carboplatin and doxorubicin exhibit distinct immunogenic cell death (ICD) 34 inducing potential, we investigated the chemotherapy specific effect in the magnitude of 35 response to exogenous STING pathway activation. Immunocompetent C57/BL6 mice were 36 implanted with ID8-Trp53 -/cells followed by treatment with carboplatin or doxorubicin. Towards 37 rationalized addition of STING agonist with or without PD-L1 blockade, we first determined the 38 expression of 60 known ICD associated genes at an early time point following the initial treatment 39 with carboplatin or doxorubicin with or without STING agonist. Doxorubicin treated tumours 40 showed significantly higher expression of ICD genes, Cxcl10, Cd274, Isg15, 41
Psmb9 and Calr. Expression changes were further amplified following the addition of STING 42 agonist. Significantly higher expression of Cxcl10 and Isg15 were observed in the doxorubicin + 43 STING agonist treated mice compared to carboplatin + STING agonist combination. 44
Interestingly, Ccl5 gene expression was higher in the tumours from carboplatin or carboplatin and 45 STING agonist combination treated mice compared to those treated with doxorubicin. Plasma 46 cytokine analysis showed distinct profiles of CXCL10, CCL5, MCP-1 and IL6 post treatment with 47 each chemotherapy type. Doxorubicin monotherapy treated mice showed significantly longer 48
INTRODUCTION 58
High grade serous carcinoma of the ovary (HGSC) is a deadly disease with a five-year survival 59 rate of just 45.6% that has seen little improvement over the past few decades 1,2 . The poor survival 60 rate of HGSC patients can be attributed to a variety of factors including diagnosis at later 61 stages and high rates of resistance and recurrence 3 . Indeed, the majority of women diagnosed with 62 HGSC present with advanced disease. At an advanced stage there are limited treatment options 63 such as cytoreductive surgery followed by platinum and taxane-based combination 64 chemotherapies. These treatments are largely ineffective as 70% of patients will 65 relapse progressing to platinum-resistant HSGC. While other "hard-to-treat" tumor types have 66 seen vast improvements with the integration of cancer immunotherapies, such as immune 67 checkpoint blockade (ICB), HGSC has not seen the similar success 4 . Most ICB therapies have 68 been shown to enhance the pre-existing immune landscape, specifically the presence 69 of lymphocytes that express the target immune checkpoint for blocking and subsequent activation 70 is required for effective treatment 5,6 . For example, a pre-treatment tumour immune landscape with 71 a high number of tumour infiltrating lymphocytes (TILs) is broadly defined as "hot/T-cell 72 inflamed" and in most cases predictive of better prognosis and response to ICB when compared to 73 their low TIL "cold/T cell non-inflamed" counterparts 7,8 . 74
In our previous reports, we showed the pre-treatment immune transcriptome of tumours 75 from platinum-resistant HGSC patients are intrinsically immunologically cold 9,10 . We 76 demonstrated that a non-inflamed pre-existing T helper type I tumor immune microenvironment 77 (TIME), decreased expressions of type I interferon (IFN1) genes and STAT1 protein, low density 78 of TILs associated with poor response to chemotherapy 10 . Strategies attempting to 79 transform these immunologically cold tumors to hot, thus improving therapeutic response through 80 IFN1 activation, have recently garnered tremendous interest across solid tumours 8, 11 . 81
One such example is using immune activating agents, including those that 82 activate (cGAS)-Stimulator of Interferon Genes (STING) pathway ( Figure 1A ). Activation 83 of STING pathway primarily occurs via cytosolic nucleic acid sensing that leads to increased 84 production of IFN induced genes, specifically the TIL recruiting CXCR3 85 binding chemokines, CXCL9/10/11 and CCL5 [11] [12] [13] .
Supporting this hypothesis, 86
we previously reported that response to platinum chemotherapy can be improved via incorporating 87 STING agonist post carboplatin chemotherapy. In this pre-clinical study using the ID8-Trp53 -88 /syngeneic murine model of HGSC, we also showed the immune sensitizing potential of STING 89 agonist to programmed cell death protein-1 (PD-1) ICB 12 . Addition of STING agonist to the 90 treatment regimen significantly improved survival both when administered as a monotherapy 91 and in combination with carboplatin and PD-1 ICB . Potentially attributed to 92 the angiostatic function of CXCL10 chemokine, treatment with STING agonist also reduced 93 ascites formation and overall tumor burden. Additionally, an enrichment of genes associated with 94 antigen presentation, MHCII, IFN response, and increased expression of Stat1 and Cxcl10 leading 95 to overall enhancement of IFN1 immune responses in the TIME, were observed in the tumours 96 from mice treated with STING agonist 12 . 97
While these results provide a strong rationale for testing these combination treatment 98 approaches for patients with platinum-sensitive tumors, as previously mentioned, many patients 99 progress to develop platinum-resistant HGSC 1,14 . Patients with recurrent HGSC are administered 100 second line chemotherapies including doxorubicin, an anthracycline known to be 101 a bonafide inducer of immunogenic cell death (ICD). ICD is an immune priming form of cell death 102 which occurs following exposure to a subset of cytotoxic chemotherapies or radiotherapy 15-103 17 . Chemotherapy induced ICD can increase tumour antigen recognition and cross presentation by 104 dendritic cells or macrophages to cytotoxic TILs in the sterile TIME. Following this logic, ICD 105 inducing chemotherapies have been combined with ICB to further augment anti-tumor 106 immunity 18 . In addition to their ICD inducing effects, anthracyclines, including doxorubicin, have 107 also been reported to increase PD-L1 expression on tumor cells predicting a stronger rationale 108 for combination with ICB anti-PD-L1 treatment 19, 20, 21 . 109
Based on these compelling findings, we sought to compare the efficacy of immune 110 activating STING agonist when combined with a stronger ICD inducer -doxorubicin in the ID8-111
Trp53 -/model of HGSC. We hypothesized that the effects we previously reported with a 112 combination of carboplatin and STING agonist, could be further potentiated with a stronger ICD 113 inducer such as doxorubicin. Based on our previous finding that STING agonist treatment led to 114 increased tumour and splenic myeloid derived suppressor cell specific PD-L1 expression, we 115 further evaluated the impact of combination with PD-L1 ICB on overall survival. Findings from 116 our study provide novel directions for the precise use of therapies activating STING pathway in 117 combination with ICD inducing chemotherapy. 118 119
METHODS 120

Cell lines 121
The ID8-Trp53 -/mouse ovarian surface epithelial cells were kindly provided by Dr. To determine the effect of chemotherapy type and combination with STING agonist, on the 143 systemic cytokine profiles, plasma samples collected at 24 h time point following first STING 144 agonist treatment post either carboplatin or doxorubicin treatment, were subjected to multiplexed 145 cytokine profiling using the MD31, 31-plex cytokine/chemokine array (Eotaxin, G-CSF, GM-146 CSF, IFN gamma, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), 147 IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, CXCL1, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1alpha, 148 MIP-1beta, MIP-2, RANTES, TNF alpha, VEGF) at Eve Technologies Corporation (Calgary, 149 AB, Canada). All samples were analysed in biological triplicates. The standard curve regression 150 was used to calculate the concentration of each target cytokine. Differences between levels of 151 cytokines were analysed using GraphPad Prism (7.02). 152 153
Tumour ICD gene expression profiling using a custom NanoString panel 154
To determine the ICD effect induced by carboplatin and doxorubicin chemotherapy and 155 subsequent effects post addition of STING agonist, total RNA from tumours collected 24 h post 156 first STING agonist treatment and the chemotherapy only controls,A were subjected 157
to NanoString based gene expression profiling using a custom ICD gene panel (Table 1) . 158
Briefly, total RNA from fresh frozen tumour tissues was isolated using the total RNA Purification Differentially expressed genes between the tumours from different treatment groups were derived 171 using GraphPad Prism software. A p-value <0.05 was considered statistically significant. 172 173 RESULTS 174
Doxorubicin induces a higher and distinct expression of ICD genes compared to 175 carboplatin in ID8-Trp53 -/tumours 176
The expression of 60 ICD associated genes was measured in RNA isolated from tumours of mice 177 treated with carboplatin or doxorubicin monotherapy (Figure 2A and 2B). Genes specifically 178 associated with IFN1 pathways, including, Ifna1, Ifnb1, Psmb9 and Cxcl10, showed 179 significantly (p<0.05) higher expression in doxorubicin treated mice compared to those treated 180 with carboplatin ( Figure 2B ). Interestingly, Ccl5 expression was higher in carboplatin treated 181 tumours compared to those treated with doxorubicin. 182
183
STING activation alters expression of tumour ICD associated genes in a chemotherapy 184 specific manner 185
Addition of STING agonist post chemotherapy showed significant differences in the magnitude of 186 ICD gene expression in tumours ( Figure 3A ). In general, doxorubicin + STING 187 agonist combination showed significantly (p<0.05) higher expression of Stat3, Casp8, Ifna1, 188 Ido1, Prf1, CD274, Ifnb1, Casp1, Isg15, Stat1, Cxcl10, Psmb9, H2k1 and H2d1, compared to 189 carboplatin chemotherapy ( Figure  3B ). Interestingly, however, the 190 expression of Cxcl9, Calr and Ccl5 was significantly higher in carboplatin + STING agonist 191 treated tumours compared to those treated with doxorubicin ( Figure 3B ) indicative of their possible 192 differential expression in cancer cells compared to immune cells. 193
STING agonist amplifies doxorubicin mediated cytokine production 195
To determine the chemotherapy associated differences in plasma cytokine levels, we conducted 196 multiplex cytokine analysis of plasma collected at 24 h post first treatment with carboplatin, 197 doxorubicin or untreated controls. Doxorubicin only treated mice showed elevated plasma levels 198 if CXCL10, MCP-1, MIP-1B compared to those treated with carboplatin, however this difference 199 was not statistically significant ( Figure 4) . Notably, the levels of CCL5 and IL-6 were significantly 200 higher in doxorubicin treated mice compared to those treated with carboplatin ( Figure 4) . 201
The addition of STING agonist further elevated CXCL10 levels in the plasma 202 of carboplatin and doxorubicin treated mice, however the difference between the two 203 chemotherapy types was not significant ( ICB was based on post treatment tumour gene expression profiling that showed increased levels 215
of Cd274 (gene encoding PD-L1) following addition of STING agonist. 216
Comparison of chemotherapy types as single agents revealed 217 that doxorubicin treated mice had significantly longer overall survival (average of 96.5 days) than 218 carboplatin treated mice (average of 77 days; Figure 5 ). In line with our previously reported 219 findings, addition of STING agonist significantly increased the survival of carboplatin treated 220 mice by an average of 13 days ( Figure 5 ). Although, the addition of anti-PD-L1 to carboplatin did 221 not show any significant increase in overall survival, treatment with anti-PD-L1 following 222 treatment with STING agonist and carboplatin chemotherapy significantly extended the median 223 overall survival to 101 days ( Figure 5B ). 224
Surprisingly, upon addition of STING agonist or anti-PD-L1, we did not 225 observe significantly increased survival advantage in the doxorubicin treated mice, with a modest 226 increase in survival of 4 and 3.5 days respectively. Overall survival of doxorubicin 227 + STING + anti-PD-L1 combination was, however, significantly increased to an average of 103 228 days ( Figures 5A and B) . thus improving response to conventional chemotherapy and novel ICB 12 . Importantly, our previous 237 report showed that direct activation of STING pathway can enhance response to carboplatin 238 chemotherapy and sensitize tumours to PD-1 ICB. 239
Patients with HGSC have minimally benefited from the newer ICB therapies indicating the 240 lack of understanding in how the effect of ICB is dependent on the pre-existing TIME 22 . It is well 241 established that HGSC tumours exhibit high genomic instability and thus are thought to be 242 immunogenic, contributing to immunologically variant states that can be identified at the time of 243 diagnosis or primary debulking surgery 23 . In line with these characteristics, we and others have 244 previously shown that pre-existing immunologically divergent states also associate with 245 chemotherapy response and overall survival, indicating the significance of IFN induced 246 chemokines and associated ICD in mediating treatment response 10,24 . It is important to note that a 247 growing body of evidence suggests a co-existence of inflamed and non-inflamed states across 248 multiple regions in one given tumour 25 . However, irrespective of their classification, the density, 249 localization and activation state of immune cells in the TIME could greatly impact variability 250 in therapeutic response to immune based therapies, in addition to the type of chemotherapy 26, 27 . 251
The level of ICD response elicited by chemotherapies is one example of a mechanism 252 dependent on the pre-existing TIME. Specifically, ICD events lead to a release in danger associated 253 molecular pattern (DAMP) in a spatiotemporal manner that can have a profound impact on the 254 consequent activation of both innate and adaptive immune response. Therefore, a comprehensive 255 understanding of treatment induced ICD events is critical for the design of 256 rationalistic ICB combinations 28,29 . While radiation is the most potent ICD inducing therapy, 257 chemotherapeutic agents such as anthracyclines, platinum, taxanes and other agents promote 258 variable degrees of ICD events that ultimately alter tumour immunogenicity 30,31 . Along this 259 notion, it can be speculated that inflamed tumours with high pre-existing activated TILs and 260
IFN gene expression will produce a higher magnitude of immune-mediated responses compared 261
to non-inflamed tumours given the proximity of intra-tumourally located TILs. Indeed, ongoing 262 Surprisingly, the expression of Ccl5 gene was significantly higher in carboplatin and carboplatin 286 + STING agonist treated tumours compared to those treated with doxorubicin and doxorubicin 287 +STING agonist. This finding is suggestive of potential differences in cancer cell and immune cell 288 specific STING pathway activation and warrants further investigation. 289
When used as a single agent, doxorubicin treated mice had a significant 290 increase in survival compared to those treated with carboplatin. Similar to our previous findings, 291 the significant increase in survival following addition of STING agonist to either carboplatin or 292 doxorubicin treated tumours strongly suggests that immunomodulation via STING pathway 293 activation post chemotherapy could be a promising approach to improve response to carboplatin 294 chemotherapy. Surprisingly, survival was not further prolonged following the addition of STING 295 agonist in the doxorubicin treated mice, and therefore we observed for the first time that response 296 to doxorubicin treatment may not achieve the level of improvement as seen with carboplatin from 297 the addition of STING agonist. Our leading explanation for this finding is the differential ICD 298 response produced by doxorubicin and carboplatin 36 . Doxorubicin itself is known to induce IFN1 299 response via STING pathway activation and downstream chemokine induction and therefore the 300 addition of STING agonist may not significantly increase immune activation in the doxorubicin 301 treated TIME 37 . 302
Tumour immune transcriptomic profiles 24 hours post chemotherapy and STING agonist 303 treatment showed significant increase in expression of Cd274 (gene encoding PD-L1). 304 Furthermore, in our previous report we observed increased levels of PD-L1 in splenic myeloid 305 derived suppressor cells post addition of STING agonist to carboplatin. We thus added anti-PD-306 L1 to the treatment regimen. Interestingly, the addition of anti-PD-L1 ICB to the doxorubicin + 307 STING agonist treated group did not add further survival benefit. This was indeed an 308 unexpected finding given the large impact it had on survival following carboplatin 309 treatment. However, doxorubicin is known to impact PD-L1 expression, such as decreased surface 310 expression and increased nuclear expression on breast cancer cells 38 . This altered expression could 311 potentially have impacted the response to anti-PD-L1 therapy in this study. Another possible 312 reason could be the increased IL-6 level post doxorubicin treatment, which was amplified by a 313 magnitude of >15 fold upon addition of STING agonist. As previously reported, the significant 314 increase in IL6 might have contributed to lack of survival benefit in these mice due to its 315 immunosuppressive effects on CD4+ T cells and increasing cancer cell PD-L1 expression 39 . IL-6 316 promotes the survival of cancer cells and is usually associated with poor prognosis across cancer 317 types. Importantly, in the context of immunotherapies, high IL-6 level is the key indicator of 318 cytokine release syndrome that is usually associated with immune related adverse events 40, 41 . 319
Moreover, IL-6 is well known to be associated with chemotherapy resistance in HGSC, as 320 previously reported by us and others 10 . As recently shown in melanoma models, blockade of IL-6 321 following STING agonist treatment post doxorubicin treatment might prolong survival via 322 augmenting T helper type I response 39 . However, a significant increase in survival was 323 observed when doxorubicin, STING agonist and anti-PD-L1 were used in combination. Blockade 324 of IL6 in these mice post addition of STING agonist may potentially lead to an increased survival 325 benefit. 326
With growing awareness that the TIME is both impacted by and impacts the efficacy of 327 cancer therapies, it's imperative that combination immunotherapy strategies are rationally 328
designed. This study is the first to directly compare the combination of STING agonists with 329 differential chemotherapies within the same model and importantly identifies that chemotherapy 330 combinations with STING can mimic the TIME effects of a strong ICD inducer for precise immune 331 sensitization for PD-L1 ICB. This key finding suggests that in the development of combination 332 immunotherapeutic strategies to avoid high-dose toxicity associated with chemotherapies, other 333 agents inducing immune-stimulating pathways can be co-administered to prevent toxicities while 334 eliciting similar immune stimulating effects. 335
Our study significantly advances the field of STING pathway activation based immune 336 sensitization of tumours, however, there are some limitations to our study design. Since our 337 question was primarily to evaluate in vivo differences in the synergistic effect of STING activation 338 with different chemotherapy types and PD-L1 ICB, we did not perform the gold standard ICD 339 induction assay in cancer cells prior to implantation in mice, as suggested by the consensus ICD 
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The authors declare no competing interests. to build the heatmaps in R Bioconductor statistical environment. 468
Doxorubicin induces differential ICD gene expression compared to carboplatin (2B). A 60 469
gene custom ICD NanoString panel was applied to measure the expression of genes associated 470 with ICD pathways. Kruskal Wallis test was applied to compare the median between the three 471 groups. Data analysis was performed using R Bioconductor. p-value<0.05 (*) was considered 472 statistically significant. 
STING agonist affects the expression of ICD genes in chemotherapy specific manner (3B). 479
Tumours from doxorubicin + STING agonist (SA) treated mice and carboplatin + SA treated mice 480 were subjected to ICD gene expression profiling using a custom NanoString panel. Kruskal Wallis 481 test was applied to compare the median between the three groups. Data analysis was performed 482 using R Bioconductor. p-value<0.05 (*) was considered statistically significant. 
Figure 2B. Doxorubicin induces differential ICD gene expression compared to carboplatin.
A 60 gene custom ICD NanoString panel was applied to measure the expression of genes associated with ICD pathways. Kruskal Wallis test was applied to compare the median between the three groups. Data analysis was performed using R Bioconductor. p-value<0.05 (*) was considered statistically significant.
No Treatment
Carboplatin + SA Doxorubicin + SA Figure 3A . STING agonist potentiates doxorubicin induced ICD. Heat map showing differential expression pattern of 60 ICD associated genes in tumours from mice treated with carboplatin + STING agonist (SA) compared to doxorubicin + SA. Scale function was used to center the expression scores and ComplexHeatmap package was used to build the heatmaps in R. Figure 3B . STING agonist affects the expression of ICD genes in chemotherapy specific manner. Tumours from doxorubicin + STING agonist (SA) treated mice and carboplatin + SA treated mice were subjected to ICD gene expression profiling using a custom NanoString panel. Kruskal Wallis test was applied to compare the median between the three groups. Data analysis was performed using R Bioconductor. p-value<0.05 (*) was considered statistically significant. 
